Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BELLUS Health Inc. (T:BLU)

Business Focus: Pharmaceuticals

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for BLU within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 15, 2019 11:00 ET
BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it will convene a Key Opinion Leader meeting to discuss chronic cough on Tuesday, July 16, 2019 in New York City. The event will include discussions on the unmet medical need in the category, and a review of current therapies in development including P2X3 antagonists. BELLUS Health will also provide clinical and regulatory updates on its lead P2X3 antagon
Read full article
May 21, 2019 16:15 ET
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today presented results from the clinical Phase 1 study of BLU-5937, an orally-administered P2X3 antagonist, being developed for the treatment of refractory chronic cough. Clinical data presented at the American Thoracic Society International Conference in Dallas, Texas showed that BLU-5937 is well-tolerated and importantly, pr
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.19
--
--
Price to Sales - TTM
13,567.25
6.50
15.73
Price to Book - most recent quarter
10.19
3.49
3.09
Price to Cash Flow per share - TTM
--
9.33
14.45
Price to Free Cash Flow per share - TTM
--
9.76
11.91
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 201944,551-5,480
Jun 15, 201950,03130,338
May 31, 201919,693-803,712
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
What drove BELLUS Health shares up? Here's our take via the Jun 26 INK morning report (video summary) $BLU.CA $MRK https://www.canadianinsider.com/blog/video-summary-berger-buys-bellus-health-stock-blasts-higher
Jun 27, 2019 03:51 am

Twitter

Search (past week) for $BLU.CA

  • No tweets found

StockTwits

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
What drove BELLUS Health shares up? Here's our take via the Jun 26 INK morning report (video summary) $BLU.CA $MRK https://www.canadianinsider.com/blog/video-summary-berger-buys-bellus-health-stock-blasts-higher
Jun 27, 2019 03:51 am

Twitter

Search (past week) for $BLU.CA

  • No tweets found

StockTwits